ArticleScientific reports2022
Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review.BMC infectious diseases · 2023Pooled it
- Tick-borne encephalitis in the Åland Islands, Finland: incidence and disease course since the implementation of a general TBE vaccination programme.Emerging microbes & infections · 2026Article
- Prevention of neuroinfectious-diseases: high impact of vaccination programs - but the potential is not maxed out yet.Neurological research and practice · 2026Review
- Tick-Borne Encephalitis Vaccine Effectiveness and Impact in Slovenia, 2019-2024.Pathogens (Basel, Switzerland) · 2026Article
- The Lyme Disease Vaccine Paradox.Journal of clinical medicine · 2026Article
- Using protection motivation theory to explain intentions to vaccinate against tick-borne encephalitis.BMC public health · 2025Article
- Fast-Track to Protection? A Review of Encepur's Express Dosing Schedule for Tick-Borne Encephalitis.Viruses · 2025Review
- Tick-borne encephalitis vaccine effectiveness and public health impact in the Baltic countries of Estonia, Latvia, and Lithuania, 2019-2023.IJID regions · 2025Article
- Article
- Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022.Scientific reports · 2025Article
- Article
- Attitudes towards the Tick-Borne Encephalitis Vaccine among Children's Guardians: A Cross-Sectional Survey Study in Poland.Vaccines · 2024Article
- A combined cross-sectional analysis and case-control study evaluating tick-borne encephalitis vaccination coverage, disease and vaccine effectiveness in children and adolescents, Switzerland, 2005 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Defining the "Correlate(s) of Protection" to tick-borne encephalitis vaccination and infection - key points and outstanding questions.Frontiers in immunology · 2024Review
- Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2023Article
- Recovery and sequelae in 523 adults and children with tick-borne encephalitis in Germany.Infection · 2023Article
- Impact of climate change on vector- and rodent-borne infectious diseases.Journal of health monitoring · 2023Article
- Increased Vaccination Diversity Leads to Higher and Less-Variable Neutralization of TBE Viruses of the European Subtype.Vaccines · 2023Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis (TBE) vaccination coverage remains low in Germany. Our case-control study (2018-2020) aimed to examine reasons for low vaccine uptake, vaccine effectiveness (VE), and vaccine breakthrough infections (VBIs). Telephone interviews (581 cases, 975 matched controls) covered vaccinations, vaccination barriers, and confounders identified with directed acyclic graphs. Multivariable logistic regression determined VE as 1-odds ratio with 95% confidence intervals (CI). We additionally calculated VE with the Screening method using routine surveillance and vaccination coverage data. Main vaccination barriers were poor risk perception and fear of adverse events. VE was 96.6% (95% CI 93.7-98.2) for ≥ 3 doses and manufacturer-recommended dosing intervals. Without boosters, VE after ≥ 3 doses at ≤ 10 years was 91.2% (95% CI 82.7-95.6). VE was similar for homologous/heterologous vaccination. Utilising routine surveillance data, VE was comparable (≥ 3 doses: 92.8%). VBIs (n = 17, 2.9% of cases) were older, had more comorbidities and higher severity than unvaccinated cases. However, only few VBIs were diagnostically confirmed; 57% of re-tested vaccinated cases (≥ 1 dose, n = 54) proved false positive. To increase TBE vaccine uptake, communication efforts should address complacency and increase confidence in the vaccines' safety. The observed duration of high VE may inform decision-makers to consider extending booster intervals to 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.